ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2073

Green Tea Epigallocatechin-3-Gallate Ameliorates Murine Arthritis by Inducing IDO Producing Dendritic Cells Via Nrf2 Antioxidant Pathway

Soyoun Min1, Mei Yan1, Kamala Vanarsa2, Anna Bashmakov1 and Chandra Mohan1, 1Internal Medicine/Division of Rheumatology, University of Texas Southwestern Medical Center, Dallas, TX, 2Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: animal models and type II collagen, Dendritic cells, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis: Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: To examine the immunomodulatory effects and mechanisms of Green Tea (−)-epigallocatechin-3-gallate (EGCG) on experimental arthritis in mice, we investigated whether EGCG can afford therapeutic benefit in collagen-induced arthritis (CIA) subjected mice.         

Methods: EGCG (10 mg/kg body weight) was administered by oral feeding three times per week for three weeks after booster immunization, while the control mice were administered phosphate-buffered saline (PBS). The effects of EGCG were examined by assessment of joint swelling, histological changes, and immune cell populations, and the mice were sacrificed 7 weeks after the first immunization. The level of protein obtained from spleen cells and joint homogenates was examined by Western Blotting analysis. Serum levels of anti-type II collagen specific antibodies and cytokine production were measured by ELISA.                                                                                      

Results: EGCG treatment ameliorated clinical symptoms and reduced histological scores in arthritic mice (7.2 ± 1.2 vs 12.4 ± 2.3, P < 0.01). The serum concentrations of type-II collagen-specific IgG2a antibodies were significantly lower in EGCG-fed mice compared to PBS-treated mice (0.105 ± 0.01vs 0.283 ± 0.25 OD units, P < 0.05). EGCG significantly suppressed T cell activation by reducing [3H]-thymidine uptake and cell division as assessed by CFSE dilution. EGCG also reduced CD4 and CD8 T cells, B cells, marginal zone B cells, T1 and T2 transitional B-cells in the draining lymph node (dLN) and spleen, suggesting that down-regulation of several immune cell populations is one of the mechanisms of EGCG action. EGCG treatment increased the frequency of CD4+ Foxp3+ regulatory T cells (6.4 ± 1.25% vs 1.94 ± 1.0, P < 0.05) and IDO expression within CD11b+ dLN cells. The increased CD11b+ DCs elicited by EGCG could induce CD4+CD25+ Tregs in an IDO dependent manner in vitro. Additionally, CD11b+ DCs in spleen cells and the joint homogenates from EGCG-fed mice exhibited significantly increased NF-E2-related factor-2 (Nrf-2) and heme oxygenase-1 (HO-1) compared with PBS-fed mice, alluding to the importance of anti-oxidants.                                                 

Conclusion: EGCG ameliorated experimental arthritis in mice eliciting IDO-producing DCs and the activation of the Nrf-2 anti-oxidant pathway. Our results also indicate that ECGC may be of potential therapeutic value for inhibiting cartilage destruction and increasing immunoregulatory cells in arthritic joints. It remains to be established whether EGCG is useful for the prevention and treatment of rheumatoid arthritis.


Disclosure:

S. Min,
None;

M. Yan,
None;

K. Vanarsa,
None;

A. Bashmakov,
None;

C. Mohan,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/green-tea-epigallocatechin-3-gallate-ameliorates-murine-arthritis-by-inducing-ido-producing-dendritic-cells-via-nrf2-antioxidant-pathway/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology